Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer

Hong Jun Park, Hyunsoo Kim, Bo Ra Kim, So Yeon Park, Jin Heon Hong, Ki Won Jo, Jae Woo Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear. Aims: To evaluate the efficacy of half-dose rabeprazole on endoscopic submucosal dissection-induced ulcer compared with standard dose rabeprazole. Methods: The study was a prospective randomized controlled double-blind trial at a single tertiary hospital. A total of 80 patients who underwent ESD for gastric neoplasia were enrolled. Of these patients, 10 were not followed to completion. Final analysis included the remaining 70 patients. Rabeprazole 20 or 10 mg, depending on randomization, was given orally for 4 weeks after ESD. Results: Of the 70 patients, 45 (64 %) were men, and the median age was 65.2 ± 9.7 years. The mean ESD-induced ulcer area was 673 mm2. No significant differences in ulcer area reduction ratio (p = 0.49) or ulcer-related symptoms (p = 0.91) were observed between the two groups at 4 weeks after ESD. Conclusion: For ESD-induced ulcers, treatment with 10 mg of rabeprazole daily produces a similar outcome as 20 mg of rabeprazole with regard to healing efficacy and symptom resolution.

Original languageEnglish
Pages (from-to)1054-1061
Number of pages8
JournalDigestive Diseases and Sciences
Volume58
Issue number4
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Rabeprazole
Ulcer
Endoscopic Mucosal Resection
Proton Pump Inhibitors
Stomach Ulcer
Random Allocation
Tertiary Care Centers
Stomach

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Park, Hong Jun ; Kim, Hyunsoo ; Kim, Bo Ra ; Park, So Yeon ; Hong, Jin Heon ; Jo, Ki Won ; Kim, Jae Woo. / Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer. In: Digestive Diseases and Sciences. 2013 ; Vol. 58, No. 4. pp. 1054-1061.
@article{48a806c802e34df4a9e05e2fcdb55c16,
title = "Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer",
abstract = "Background: Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear. Aims: To evaluate the efficacy of half-dose rabeprazole on endoscopic submucosal dissection-induced ulcer compared with standard dose rabeprazole. Methods: The study was a prospective randomized controlled double-blind trial at a single tertiary hospital. A total of 80 patients who underwent ESD for gastric neoplasia were enrolled. Of these patients, 10 were not followed to completion. Final analysis included the remaining 70 patients. Rabeprazole 20 or 10 mg, depending on randomization, was given orally for 4 weeks after ESD. Results: Of the 70 patients, 45 (64 {\%}) were men, and the median age was 65.2 ± 9.7 years. The mean ESD-induced ulcer area was 673 mm2. No significant differences in ulcer area reduction ratio (p = 0.49) or ulcer-related symptoms (p = 0.91) were observed between the two groups at 4 weeks after ESD. Conclusion: For ESD-induced ulcers, treatment with 10 mg of rabeprazole daily produces a similar outcome as 20 mg of rabeprazole with regard to healing efficacy and symptom resolution.",
author = "Park, {Hong Jun} and Hyunsoo Kim and Kim, {Bo Ra} and Park, {So Yeon} and Hong, {Jin Heon} and Jo, {Ki Won} and Kim, {Jae Woo}",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s10620-012-2436-5",
language = "English",
volume = "58",
pages = "1054--1061",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "4",

}

Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer. / Park, Hong Jun; Kim, Hyunsoo; Kim, Bo Ra; Park, So Yeon; Hong, Jin Heon; Jo, Ki Won; Kim, Jae Woo.

In: Digestive Diseases and Sciences, Vol. 58, No. 4, 01.04.2013, p. 1054-1061.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer

AU - Park, Hong Jun

AU - Kim, Hyunsoo

AU - Kim, Bo Ra

AU - Park, So Yeon

AU - Hong, Jin Heon

AU - Jo, Ki Won

AU - Kim, Jae Woo

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background: Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear. Aims: To evaluate the efficacy of half-dose rabeprazole on endoscopic submucosal dissection-induced ulcer compared with standard dose rabeprazole. Methods: The study was a prospective randomized controlled double-blind trial at a single tertiary hospital. A total of 80 patients who underwent ESD for gastric neoplasia were enrolled. Of these patients, 10 were not followed to completion. Final analysis included the remaining 70 patients. Rabeprazole 20 or 10 mg, depending on randomization, was given orally for 4 weeks after ESD. Results: Of the 70 patients, 45 (64 %) were men, and the median age was 65.2 ± 9.7 years. The mean ESD-induced ulcer area was 673 mm2. No significant differences in ulcer area reduction ratio (p = 0.49) or ulcer-related symptoms (p = 0.91) were observed between the two groups at 4 weeks after ESD. Conclusion: For ESD-induced ulcers, treatment with 10 mg of rabeprazole daily produces a similar outcome as 20 mg of rabeprazole with regard to healing efficacy and symptom resolution.

AB - Background: Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear. Aims: To evaluate the efficacy of half-dose rabeprazole on endoscopic submucosal dissection-induced ulcer compared with standard dose rabeprazole. Methods: The study was a prospective randomized controlled double-blind trial at a single tertiary hospital. A total of 80 patients who underwent ESD for gastric neoplasia were enrolled. Of these patients, 10 were not followed to completion. Final analysis included the remaining 70 patients. Rabeprazole 20 or 10 mg, depending on randomization, was given orally for 4 weeks after ESD. Results: Of the 70 patients, 45 (64 %) were men, and the median age was 65.2 ± 9.7 years. The mean ESD-induced ulcer area was 673 mm2. No significant differences in ulcer area reduction ratio (p = 0.49) or ulcer-related symptoms (p = 0.91) were observed between the two groups at 4 weeks after ESD. Conclusion: For ESD-induced ulcers, treatment with 10 mg of rabeprazole daily produces a similar outcome as 20 mg of rabeprazole with regard to healing efficacy and symptom resolution.

UR - http://www.scopus.com/inward/record.url?scp=84876543613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876543613&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2436-5

DO - 10.1007/s10620-012-2436-5

M3 - Article

C2 - 23065090

AN - SCOPUS:84876543613

VL - 58

SP - 1054

EP - 1061

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 4

ER -